Hereditary form of parkinsonism--dementia.
In four generations of a family, 13 members were afflicted with an autosomal dominant disorder characterized by young age at onset, early weight loss, and rapidly progressive dopa-responsive parkinsonism, followed later by dementia and, in some, by hypotension. Intellectual dysfunction began with subjective memory loss and objective visuospatial dysfunction and was followed later by decline of frontal lobe cognitive and memory functions. Neuropathological examination in 4 autopsied cases showed neuronal loss in the substantia nigra and locus ceruleus and widespread Lewy bodies, many of them in the cerebral cortex; those in the hypothalamus and locus ceruleus were often of bizarre shapes. Other findings were vacuolation of the temporal cortex, unusual neuronal loss and gliosis in the hippocampus (CA 2/3), and neuronal loss in the nucleus basalis. There were no neuritic plaques, neurofibrillary tangles, or amyloid deposits. Positron emission tomography in 3 patients showed decreased striatal uptake of fluorodopa. Neurochemical analysis of an autopsied brain showed a pronounced decrease in choline acetyltransferase activity in the frontal and temporal cortices and hippocampus and a severe depletion of striatal dopamine with a pattern not typical of classic Parkinson's disease.
Muenter
M D
MD
Department of Neurology, Mayo Clinic Scottsdale, AZ 85259, USA.
Forno
L S
LS
Hornykiewicz
O
O
Kish
S J
SJ
Maraganore
D M
DM
Caselli
R J
RJ
Okazaki
H
H
Howard
F M
FM
Snow
B J
BJ
Calne
D B
DB
D000328:Adult; D000978:Antiparkinson Agents / Q000008:administration & dosage; D002795:Choline O-Acetyltransferase / Q000032:analysis; D003704:Dementia / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000235:genetics*; D004298:Dopamine / Q000032:analysis; D005192:Family Health; D005260:Female; D005799:Genes, Dominant; D006624:Hippocampus / Q000737:chemistry / Q000201:enzymology / Q000473:pathology; D006719:Homovanillic Acid / Q000032:analysis; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage; D016631:Lewy Bodies / Q000473:pathology; D008125:Locus Coeruleus / Q000737:chemistry / Q000473:pathology; D008297:Male; D008875:Middle Aged; D017072:Neostriatum / Q000737:chemistry / Q000473:pathology; D009410:Nerve Degeneration / Q000473:pathology; D009483:Neuropsychological Tests; D010300:Parkinson Disease / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000235:genetics*; D010375:Pedigree; D013377:Substantia Innominata / Q000737:chemistry / Q000473:pathology; D013378:Substantia Nigra / Q000737:chemistry / Q000473:pathology; D013702:Temporal Lobe / Q000737:chemistry / Q000201:enzymology / Q000473:pathology; D014055:Tomography, Emission-Computed
D000978:Antiparkinson Agents; D007980:Levodopa; D002795:Choline O-Acetyltransferase; D004298:Dopamine; D006719:Homovanillic Acid